Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease

American Journal of Hematology

Volumn 86, Issue 9, 2011, Pages 804-806

  Brandow, Amanda M ^a,b   Panepinto, Julie A ^a,b  

^a Section of Pediatric Hematology/Oncology   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HEMOGLOBIN F; HYDROXYUREA;

CHILDHOOD DISEASE; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DRUG MONITORING; DRUG SAFETY; DRUG UTILIZATION; E-MAIL; FEMALE; HEALTH SURVEY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERVIEW; LETTER; LEUKOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; MEDICAL SOCIETY; NEUTROPHIL COUNT; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; RELIABILITY; SICKLE CELL ANEMIA; THROMBOCYTE COUNT;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; CROSS-SECTIONAL STUDIES; DRUG MONITORING; ELECTRONIC MAIL; ERYTHROCYTE INDICES; FETAL HEMOGLOBIN; HUMANS; HYDROXYUREA; LEUKOCYTE COUNT; MAXIMUM TOLERATED DOSE; MEDICATION ADHERENCE; NEUTROPHILS; PHYSICIAN'S PRACTICE PATTERNS; PLATELET COUNT; QUESTIONNAIRES; TIME FACTORS; UNITED STATES;

EID: 80051815757     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22101     Document Type: Letter

References (21)

1. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: Results of a 17-year, single-center trial (LaSHS). Blood 2010; 115: 2354-2363.
2. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003; 289: 1645-1651.
3. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 1995; 332: 1317-1322.
4. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial. Blood 1996; 88: 1960-1964.
5. Brandow AM, Jirovec DL, Panepinto JA. Hydroxyurea in children with sickle cell disease: Practice patterns and barriers to utilization. Am J Hematol 2010; 85: 611-613.
6. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: Hydroxyurea treatment for sickle cell disease. Ann Internal Med 2008; 148: 932-938.
7. Lanzkron S, Haywood C Jr, Hassell KL, Rand C. Provider barriers to hydroxyurea use in adults with sickle cell disease: A survey of the Sickle Cell Disease Adult Provider Network. J Natl Med Assoc 2008; 100: 968-973.
8. Zumberg MS, Reddy S, Boyette RL, et al. Hydroxyurea therapy for sickle cell disease in community-based practices: A survey of Florida and North Carolina hematologists/oncologists. Am J Hematol 2005; 79: 107-113.
9. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 2010; 115: 5300-5311.
10. Thornburg CD, Calatroni A, Telen M, Kemper AR. Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr 2010; 156: 415-419.
11. Sichle Cell Disease Guidelines-Hydroxyurea Chapter. Accessed November 21, 2011.
12. de Montalembert M, Brousse V, Elie C, et al. Long-term hydroxyurea treatment in children with sickle cell disease: Tolerance and clinical outcomes. Haematologica 2006; 91: 125-128.
13. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004; 103: 2039-2045.
14. Burgess SWSP, Morawska A, Devadason SG. Assessing adherence and factors associated with adherence in young children with asthma. Respirology 2008; 13: 559-563.
15. Jentzsch NS, Camargos PA, Colosimo EA, Bousquet J. Monitoring adherence to beclomethasone in asthmatic children and adolescents through four different methods. Allergy 2009; 64: 1458-1462.
16. Thornburg CD, Calatroni A, Telen M, Kemper AR. Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr 2010; 156: 415-419.
17. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
18. Franklin VL, Waller A, Pagliari C, Greene SA. A randomized controlled trial of Sweet Talk, a text-messaging system to support young people with diabetes. Diabet Med 2006; 23: 1332-1338.
19. Lee SJ, Joffe S, Kim HT, et al. Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation. Blood 2004; 104: 2194-2200.
20. Wong EC, Perez-Albuerne E, Moscow JA, Luban NL. Transfusion management strategies: A survey of practicing pediatric hematology/oncology specialists. Pediatr Blood Cancer 2005; 44: 119-127.
21. Streiff MB, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: A survey of American Society of Hematology members' practice patterns. Blood 2002; 99: 1144-1149.